Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at Goldman Sachs Global Healthcare Conference Transcript

Jun 16, 2022 / 05:00PM GMT
Release Date Price: R$56.97
Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Welcome, everyone, to our highlight, final presentation at the Goldman Sachs Healthcare Conference. We are so honored that J&J could come join us for this, apropos in so many ways, getting in the last word as they say. My name is Chris Shibutani. I'm a member of the research team. I cover pharmaceuticals and biotechnology.

Very quickly, I'll steal a moment from J&J and say thank you to so many folks who have pulled together this event. Just a tremendous amount of effort, a display of excellence across so many domains, within our conference planners, people who are too many to shout out, but obviously, this has been a tremendous effort.

Thank you also to our clients who joined together with us, took this bold step to be in person, I think, genuinely worthwhile, and we're seeing that manifest. I think this was an event that will continue to have opportunities, seeds of breathing through how we're going to continue to think about things, for the balance of this year. So thank you so much.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot